Servier is a privately owned pharmaceutical company, governed by a non-profit foundation that’s committed to therapeutic progress to serve patient needs. Servier has a long-standing commitment to research and development. Servier has significant investment in new products in early development in the areas of Oncology and Haematology with broad research and development platforms in cancer cell apoptosis and immuno-oncology. Servier is proud to support innovative partnering programs with world class institutions including WEHI in Australia to further advance scientific understanding in the area of oncology. Servier Australia’s oncology products include Lonsurf® (trifluridine/tipiracil), Onivyde® (nanoliposomal irinotecan as sucrosofate) and Oncaspar